Zhu Yi
$12.44B
as of 02/16/26
About Zhu Yi
Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.
The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024.
Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide.
Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
Personal stats
Citizenship
People's Republic of ChinaSource of wealth
PharmaceuticalsResidence
Chengdu, SichuanBirth date
12/01/63 (age 62)Self-made
self-madeZhu Yi’s fortune is worth
207K
troy ounces of gold
191K
median U.S. household
124K
median U.S. income
0.249%
U.S. credit card volume
0.05%
GDP of the United States
0.037%
United States debt
Net worth history
Annual ranking
Related people
Did you know?
Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.
Net worth over time
Real-time ranking
Financial assets
SHANGHAI | 688506-CN
Sichuan Biokin PharmaceuticalImages © Forbes.com. All rights reserved.